domingo, 25 de septiembre de 2016

Advances in gene therapy for muscular dystrophies. - PubMed - NCBI

Advances in gene therapy for muscular dystrophies. - PubMed - NCBI

 2016 Aug 18;5. pii: F1000 Faculty Rev-2030. doi: 10.12688/f1000research.8735.1. eCollection 2016.

Advances in gene therapy for muscular dystrophies.


Duchenne muscular dystrophy (DMD) is a recessive lethal inherited muscular dystrophy caused by mutations in the gene encoding dystrophin, a protein required for muscle fibre integrity. So far, many approaches have been tested from the traditional gene addition to newer advanced approaches based on manipulation of the cellular machinery either at the gene transcription, mRNA processing or translation levels. Unfortunately, despite all these efforts, no efficient treatments for DMD are currently available. In this review, we highlight the most advanced therapeutic strategies under investigation as potential DMD treatments.

Free PMC Article

Public Health Genomics Knowledge Base (v1.2)

Genomics & Health Impact Update banner with DNA in background

 a person in a wheelchair


Last Updated: Sep 22, 2016

CDC Resources with and image of DNA

Seletced Insights & Reviews with various images of researchers in labortory environments

Epidemiology with an image of a crowd of people with a double helix

Translational Research with two images of people talking to a genetic counselor and an image of a hand with wrapped sequecing around it

Evidence Synthesis with an image of sequencing and a double helix

Practice & Implementation with images of people taking to a doctor and a nurse examining a child

Relevant Resources

No hay comentarios:

Publicar un comentario